Tirzepatide

Tirzepatide

5mg
€50,00 97,79 лв.
Sale price  €50,00 97,79 лв. Regular price 
Skip to product information
Tirzepatide

Tirzepatide

€50,00 97,79 лв.
Sale price  €50,00 97,79 лв. Regular price 
Size
Research profile

What is Tirzepatide?

Tirzepatide is a modified 39-amino-acid peptide that activates both GIP and GLP-1 receptors. Approved medicines containing tirzepatide exist, but this Peptara Lab item is an unapproved research material and is not pharmaceutically equivalent.

Identity and scientific context

Tirzepatide is designed as a dual incretin-receptor agonist with affinity for the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. A fatty-acid moiety supports albumin binding in regulated drug formulations.

Molecular profile

Mechanism studied

Research investigates integrated GIP and GLP-1 receptor signaling, glucose-dependent endocrine responses, appetite-related pathways, gastric emptying, lipid metabolism, and the relative contribution of each receptor.

Research map

Areas of interest

Laboratory themes include dual-receptor potency, signaling bias, structure-activity relationships, albumin binding, peptide stability, comparative incretin pharmacology, and controlled metabolic models.

Evidence

Current evidence level

Tirzepatide has substantial clinical evidence in approved pharmaceutical products. The formulation, manufacturing controls, sterility, excipients, device, and regulatory oversight of those medicines are not transferable to a research vial.

Product presentation and handling

Treat the selected vial amount only as material quantity. Record lot, analytical identity, solvent, concentration, storage, adsorption controls, and assay conditions. Do not derive a clinical dose or schedule from product variants.

Quality and batch documentation

The label, lot number, declared vial amount, and batch-specific documentation are the authoritative references for the supplied material. Any certificate should be matched to the lot number on the vial. A purity result describes analytical composition; it does not establish sterility, clinical safety, or suitability for human use.

Important scientific distinction

Published research about the molecule Tirzepatide describes specific experimental materials, formulations, doses, populations, and controlled conditions. Those findings cannot be transferred automatically to this Peptara Lab research material and are not a promise of clinical effect.

You may also like